Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/de/projekte/766-open-label-non-randomized-phase-ib-study-to-characterize-safety-tolerability-and-recommended-dose-of-edo-s101-a-first-in-class-alkylating-histone-deacetylase-inhibition-hdaci-fusion-molecule-in-combination-with-nivolumab-in-patients-with-refractory-locally-advanced-or-metastatic-melanoma/publikationen